Tulmimetostat DZR123 (CPI-0209)

Tulmimetostat DZR123 · Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Tulmimetostat DZR123 (CPI-0209), covering 2025-05-15 to 2025-05-15. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas [Phase 1, Phase 2]

See pricing